

1 **Effects of dietary interventions focused on adding base in the management of**
2 **metabolic acidosis in adults with chronic kidney disease: A protocol for**
3 **systematic review and meta-analysis of randomized clinical trials**

4
5 Sepideh Mahboobi¹, Rebecca Mollard^{1,2}, Navdeep Tangri^{2,3}, Nicole Askin⁴, Rasheda Rabbani⁵, Ahmed
6 M. Abou-Setta⁶, Dylan Mackay^{1,7}

- 7
8 1. Department of Human Nutritional Sciences, Faculty of Agriculture and Food Sciences,
9 University of Manitoba, Winnipeg, MB, Canada
10 2. Chronic Disease Innovation Center, Seven Oaks Hospital, Winnipeg, Manitoba, Canada
11 3. Department of Internal Medicine, Max Rady Faculty of Medicine, Rady Faculty of Health
12 Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
13 4. Neil John Maclean Health Sciences Library, University of Manitoba, Winnipeg, Manitoba, Canada
14 5. George and Fay Yee Centre for Healthcare Innovation, Max Rady College of Medicine, Rady
15 Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
16 6. Department of Community Health Sciences, Max Rady Faculty of Medicine, Rady Faculty of
17 Health Sciences, University of Manitoba, Winnipeg, Canada
18 7. Department of Internal Medicine, Section of Endocrinology, Max Rady Faculty of Medicine,
19 Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
20
21

22 **Name and full address of corresponding author:**

23 Dylan MacKay, Department of Food and Human Nutritional Sciences, Faculty of Agriculture and Food
24 Sciences, and Department of Internal Medicine, Section of Endocrinology, Rady Faculty of Health
25 Sciences, 196 Innovation drive, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.

26 Email: dylan.mackay@umanitoba.ca
27
28

29 **Abstract**

30 **Background:** Metabolic acidosis is a common complication of chronic kidney disease (CKD) which can
31 impair the function of multiple organs and accelerate CKD progression to kidney failure. The condition is
32 usually treated with sodium bicarbonate (NaHCO₃), which is an alkali salt. Although effective, alkali
33 therapy has numerous side effects including gastric discomfort and bloating, with many people having
34 difficulty tolerating higher doses. Research has shown that base producing fruit and vegetables may have
35 the ability to increase serum bicarbonate concentrations similar to what is achieved with alkali therapy,
36 but also provides added benefits. This systematic review aims to identify, critically-appraise and meta-
37 analyze findings from randomized clinical trials (RCTs) comparing the effects of dietary interventions,
38 including base producing fruit and vegetables, on serum bicarbonate concentrations as well as other
39 factors related to kidney function in adult patients with CKD.

40 **Methods:** RCTs (in adult participants (18 years of age or older), with CKD) will be included in the study.
41 Studies will be excluded if participants are undergoing dialysis or have chronic obstructive pulmonary
42 disease (COPD) requiring oxygen therapy. The interventions of interest are any dietary intervention
43 aimed at manipulating dietary acid load, compared with usual care, no treatment or placebo. Our primary
44 outcome measure will be changes in serum bicarbonate concentration, while other parameters related to
45 kidney function will be considered as secondary outcomes. A knowledge synthesis librarian developed a
46 literature search strategy for MEDLINE (Ovid). The search strategy was then adjusted for use in
47 Cochrane Central (Ovid), Embase (Ovid), Web of Science Core Collection (Clarivate) and CINAHL
48 (EBSCO). Two independent reviewers will select studies for eligibility in Covidence and data extraction
49 will be conducted using a custom MS Excel worksheet. We are planning to perform meta-analysis
50 wherever possible using random effects model. Standardized mean difference (95% confidence interval)
51 and risk ratio will be used to present continuous and dichotomous data, respectively. The assessment of
52 publication bias will be performed using funnel plots and Egger's regression test while I² statistics will be

53 used to assess heterogeneity. We are planning to perform subgroup analysis to deal with potential
54 heterogeneity.

55 **Discussion:** The results of this systematic review and meta-analysis will be useful in designing effective
56 dietary strategies for the management of CKD-related metabolic acidosis.

57 **Systematic review registration:** The present systematic review is registered in International
58 Prospective Register of Systematic Reviews (PROSPERO) (<https://www.crd.york.ac.uk/>, registration ID:
59 CRD42022342612).

60 **Key words:**

61 Dietary acid load, Metabolic acidosis, Chronic kidney disease, Fruit and vegetables

62

63

64 **Background**

65 Chronic Kidney Disease (CKD) is a progressive condition and is recognized as a leading health
66 concern worldwide (1, 2). The condition is categorized into 5 stages based on Glomerular
67 Filtration Rate (GFR); Early stages are asymptomatic, but can progress rapidly to kidney failure
68 within months in some individuals (3). CKD is associated with increased risk of cardiovascular
69 disease (CVD), kidney failure requiring renal replacement therapy, poor quality of life, and
70 mortality (4). The global prevalence of CKD has been estimated 13.4% (5). According to a
71 cross-sectional study, the overall estimated prevalence of stage 3 to 5 CKD in the Canadian
72 population was 71.9 per 1000 individuals, from 2010 to 2015 (6).

73 Kidneys play a crucial role in maintaining acid-base balance by reabsorbing bicarbonate from
74 filtrate and excreting acid and ammonia into urine (7). The cause of metabolic acidosis in CKD
75 is the inability of kidneys to excrete enough acid, leading to a positive H^+ balance and low CO_2
76 concentrations (13). As kidney function declines metabolic acidosis becomes a common
77 complication in people with CKD and its prevalence increases with the decline in GFR,
78 especially when GFR levels fall below $40 \text{ ml/min/1.73m}^2$ (8, 9). Although metabolic acidosis is
79 usually mild to moderate in CKD, the condition can impair different organ systems, and
80 contribute to increased morbidity and mortality (10, 11). Augmentation of inflammation, bone
81 disease exacerbation, muscle wasting, and acceleration of CKD progression are among adverse
82 effects related to metabolic acidosis (12).

83 Sodium bicarbonate ($NaHCO_3$) is an alkali salt commonly used in the treatment of metabolic
84 acidosis (14), which may improve endothelial function and muscle mass and delay kidney failure
85 (15). However, oral alkali therapy has been related to a number of side effects including gastric
86 discomfort and bloating, with many people having difficulty tolerating higher doses (16).

87 Furthermore, concerns have been raised about sodium retention, volume overload and
88 exacerbating pre-existing hypertension when sodium bicarbonate is used (17).

89 Daily acid load is mostly determined by the metabolism of dietary constituents into base or acid
90 production. Sulfur containing amino acids (abundant in animal sources of protein) lead to H⁺
91 production while fruit and vegetables are base producing (9). Dietary H⁺ reduction is hence
92 another strategy in the management of CKD-related metabolic acidosis, by reducing the intake of
93 acid producing components (such as animal proteins) as opposed to adding base by increasing
94 fruit and vegetables consumption (18).

95 Recent studies have reported that treating metabolic acidosis with fruit and vegetables might be
96 as effective as alkali therapy in improving disease state by modifying HCO₃ concentrations,
97 while also reducing blood pressure and preserving eGFR with no concerns regarding adverse
98 events (19, 20). One clinical trial has even shown that fruit and vegetables treatment not only
99 improved metabolic acidosis, but also reduced CVD risk better than NaHCO₃ (21). There is a
100 need to integrate existing findings on the effects of adding base through fruit and vegetables
101 consumption in the management of CKD-related metabolic acidosis. This proposed systematic
102 review will evaluate the efficacy and safety of using fruit and vegetables to manage metabolic
103 acidosis, as well as look at patients' compliance and tolerability, looking to identify limitations in
104 the current literature and set directions for future research.(23)

105 **Methods**

106 *Aim*

107 This systematic review aims to summarize findings from RCTs comparing dietary interventions
108 focused on adding base (via fruit and vegetables consumption) with dietary interventions

109 focusing on lowering acid load versus placebo/usual care/no treatment in the management of
110 metabolic acidosis in outpatient adults with CKD.

111 This study protocol was developed using Cochrane systematic review methodology (24) and is
112 reported according to Preferred Reporting Items for Systematic review and Meta-Analysis
113 Protocols (PRISMA-P) guidelines (25). The protocol has been registered in International
114 Prospective Register of Systematic Reviews (PROSPERO) (<https://www.crd.york.ac.uk/>,
115 registration ID: CRD42022342612).

116

117 *Study types and eligibility criteria*

118 The following study types will be eligible for inclusion: Randomized controlled trials, and cross-
119 over randomized trials on adult participants (18 years of age or older), with CKD (as diagnosed
120 using any recognized diagnostic criteria or author-defined) with eGFR between 15 and 40
121 ml/min/1.73 m² and serum bicarbonate levels of 14-24 mEq/L. Studies will be excluded if
122 participants are undergoing dialysis or have chronic obstructive pulmonary disease (COPD)
123 requiring oxygen therapy.

124

125 *Intervention and control groups*

126 Any dietary guidance or modification looking to manipulate dietary acid load will be considered
127 as an intervention. The comparators will be usual care/ no treatment or placebo.

128

129 ***Outcome measures***

130 Our primary outcome will be change in serum bicarbonate concentrations (mEq/L). Secondary
131 outcomes are systolic and diastolic blood pressure, heart rate, anthropometric measurements,
132 blood urea nitrogen (BUN), creatinine, eGFR, glucose, albumin, calcium, chloride, phosphorous,
133 potassium, sodium and HbA1c, albumin/creatinine ratio in urine samples, quality of life, reported
134 adverse effects, mortality and KDIGO (Kidney Disease Improving Global Outcomes) criteria for
135 acute kidney injury. This systematic review will also investigate the safety and tolerability of
136 dietary interventions (either increasing fruit and vegetables intake or decreasing animal proteins),
137 as well as bicarbonate therapy or placebo, in the management of metabolic acidosis in people
138 with CKD.

139

140 ***Study identification and selection***

141 A knowledge synthesis librarian (NA) developed the literature search strategy for MEDLINE
142 (Ovid) using a modified version of the SIGN RCT filter (26). This strategy was then peer-
143 reviewed by a second independent librarian using the PRESS checklist (23). The final search
144 strategy was then adjusted for use in Cochrane Central (Ovid), Embase (Ovid), Web of Science
145 Core Collection (Clarivate) and CINAHL (EBSCO). The search strategy for this systematic
146 review is presented in **Supplementary file 1**. Records retrieved by the search will be uploaded in
147 Covidence systematic review management software and screened for eligibility by two
148 independent reviewers (SM and RM). Ineligible citations will be recorded and the number and
149 reason for exclusion will be documented at the full-text article screening stage. Disagreements on
150 the eligibility of citations will be discussed by two reviewers with a third reviewer (DM) to
151 adjudicate, as required. Included citations will be limited to the English language.

152 ***Data extraction and management***

153 Data extraction will be done using forms developed, stored and managed in MS Excel
154 worksheet. Two reviewers will independently extract the data from all included studies. Any
155 concerns or disagreements will be discussed and settled between the two reviewers and a third
156 reviewer will adjudicate the issues that cannot be resolved by the two reviewers.

157 The following data will be extracted from the included studies:

- 158 • Study details: name of first author, year of publication, study period, country, study size,
159 and funding source
- 160 • Study population details: type of population (age, sex distribution, comorbidities, and
161 socioeconomic status)
- 162 • Intervention details: name, type, method of intervention, measure
163 (amount/extent/dosage), foods provided or recommended, foods instructed to avoid,
164 duration
- 165 • Outcome details: Data will be extracted at the end of the trial and at the longest reported
166 follow-up.

167 ***Risk-of-bias assessment***

168 The risk of bias will be assessed through the Cochrane Risk of Bias Tool 2.0. (27). The tool will
169 provide an assessment score in the forms of high, some concerns, and low risk of bias in each of
170 the following areas: bias arising from the randomization process, bias due to deviations from
171 intended interventions, bias due to missing outcome data, bias in measurement of the outcome,
172 and bias in selection of the reported result. Any disagreements or issues will be discussed by the
173 two reviewers or by involving a third reviewer if required.

174

175 *Data Analysis*

176 We are planning to conduct meta-analysis wherever possible, using a random effects model.

177 Continuous data will be presented as mean differences or standardized mean differences where
178 measures of the same outcome are with different scales, with 95% confidence intervals.

179 Dichotomous data will be assessed and reported as a risk ratio with 95% confidence intervals.

180 Statistical heterogeneity will be assessed between the included studies by using the I-squared (I^2)
181 statistic (28). Our assessment of publication bias will be completed through the use of funnel
182 plots (29) and using Egger's regression test (30) if there are at least 10 included trials in the
183 meta-analysis.

184 We are planning to perform a prespecified subgroup analyses investigating dietary intervention
185 method (adding base vs. reducing acid) and type of intervention (providing food vs. dietary
186 guidance only). We will also conduct sensitivity analyses looking at diabetes comorbidity
187 (people with diabetes vs. those without diabetes using regression against proportion of people
188 with diabetes in trial cohort), trial type (parallel vs. crossover) sex, CKD stage, and geographical
189 region.

190

191 **Discussion**

192 Metabolic acidosis is of the most common consequences of CKD, with a leading role in CKD-
193 related morbidity and mortality (31). Data from both observational and interventional studies has
194 shown that correction of metabolic acidosis by NaHCO₃ or diets rich in base producing fruit and
195 vegetables may have the ability to slow the rate of decline in kidney function (32). Patients on
196 Na⁺-based alkali therapy are at an increased risk of worsened hypertension or volume control,
197 especially at lower eGFR (33). On the other hand, the usual dietary habits of developed countries
198 often result in diets with increased production of acid equivalents (34). Therefore, dietary
199 interventions targeting the addition of base producing fruit and vegetables may be more
200 appropriate than alkaline therapy in the management of CKD induced metabolic acidosis. Some
201 small single center trials have been conducted on the effects of fruit and vegetables consumption
202 on different outcomes related to kidney function, in different stages of CKD. Some review
203 articles have included effects of dietary interventions in the management of CKD (34, 35) which
204 have provided general information in the topic. To the best of our knowledge, our study will be
205 the first to systematically review data from randomized studies aiming at evaluating the effects
206 of adding dietary base equivalents via fruit and vegetables consumption in the management of
207 CKD-related metabolic acidosis. Our study is not obstacle-free. The number of studies meeting
208 our criteria might be few and heterogeneity might arise due to different settings and clinical
209 stages. Nevertheless, we have prepared a plan for prespecified subgroup analysis based on
210 dietary interventions (adding base vs. reducing acid), type of intervention (providing food vs.
211 recommendation only), sex, diabetes comorbidity, CKD stages and region. The findings of this
212 study will be useful to guide clinical practice regarding the use of base producing fruit and

213 vegetables as an alternative option to oral alkali therapy. Furthermore, this study will find
214 limitations of the current literature and inform the design of future research in this area

215 **Abbreviations**

216 BUN: Blood Urea Nitrogen; CKD: Chronic Kidney Disease; COPD: Chronic Obstructive
217 Pulmonary Disease; CVD: Cardiovascular Disease; GFR: Glomerular Filtration Rate; KDIGO:
218 Kidney Disease Improving Global Outcomes; PRISMA-P: Preferred Reporting Items for
219 Systematic review and Meta-Analysis Protocols; PROSPERO: Prospective Register of
220 Systematic Reviews; RCT: Randomized Clinical Trial

221 **Supplementary information**

222 Supplementary file 1: search strategy

223 Supplementary file 2: PRISMA-P 2015 checklist

224 **Acknowledgement**

225 We would like to thank Tyler Ostapyk for conducting the PRESS review of our search strategy.

226

227 **Authors contribution**

228 SM drafted the review protocol manuscript. NA is a health sciences librarian who developed the
229 search strategy based on input from DM, RM, AMAS, RR NT and SM. AAB and RB provided
230 content expertise in knowledge synthesis and meta-analysis. NT provided content expertise in
231 chronic kidney disease. RM and DM are content experts in nutritional interventions. Each author
232 reviewed and made substantial contributions to this manuscript. All authors have read and
233 approved the final manuscript.

234 **Funding**

235 This study is funded by University of Manitoba and Seven Oaks Chronic Disease Innovation
236 Centre.

237 **Availability of data and material**

238 The Endnote database, as well as final extraction sheets and data regarding risk of bias
239 assessment will be available upon request.

240 **Competing interest**

241 None

242 **Ethics approval and consent to participate**

243 Not applicable

244 **Consent for publication**

245 Not applicable

246

247 **References**

248

- 249 1. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. *The Lancet*.
250 2021;398(10302):786-802.
- 251 2. Lv J-C, Zhang L-X. Prevalence and Disease Burden of Chronic Kidney Disease. In: Liu B-C, Lan H-Y,
252 Lv L-L, editors. *Renal Fibrosis: Mechanisms and Therapies*. Singapore: Springer Singapore; 2019. p. 3-15.
- 253 3. Levey AS, Coresh J. Chronic kidney disease. *The Lancet*. 2012;379(9811):165-80.
- 254 4. Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al. Complications
255 of chronic kidney disease: current state, knowledge gaps, and strategy for action. *Kidney international*
256 supplements. 2017;7(2):122-9.
- 257 5. Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, et al. Global Prevalence of
258 Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *PLOS ONE*. 2016;11(7):e0158765.
- 259 6. Bello AK, Ronksley PE, Tangri N, Kurzawa J, Osman MA, Singer A, et al. Prevalence and
260 Demographics of CKD in Canadian Primary Care Practices: A Cross-sectional Study. *Kidney*
261 *International Reports*. 2019;4(4):561-70.
- 262 7. Nagami GT, Hamm LL. Regulation of Acid-Base Balance in Chronic Kidney Disease. *Advances in*
263 *chronic kidney disease*. 2017;24(5):274-9.
- 264 8. Stancu S, Mircescu G, Mocanu A, Capusa C, Stefan G. Metabolic Acidosis of Chronic Kidney
265 Disease and Cardiovascular Disorders. *Maedica*. 2018;13(4):267-72.
- 266 9. Raphael KL. Metabolic Acidosis in CKD: Core Curriculum 2019. *American journal of kidney*
267 *diseases : the official journal of the National Kidney Foundation*. 2019;74(2):263-75.
- 268 10. Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment.
269 *American journal of kidney diseases : the official journal of the National Kidney Foundation*.
270 2005;45(6):978-93.
- 271 11. Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with
272 chronic kidney disease. *Kidney International*. 2005;67:S21-S7.
- 273 12. Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney
274 disease. *Pediatric Nephrology*. 2011;26(1):19-28.
- 275 13. Raphael KL. Metabolic Acidosis in CKD: Core Curriculum 2019. *American Journal of Kidney*
276 *Diseases*. 2019;74(2):263-75.
- 277 14. Nolan CR, Califano JR, Butzin CA. Influence of calcium acetate or calcium citrate on intestinal
278 aluminum absorption. *Kidney International*. 1990;38(5):937-41.
- 279 15. Chen W, Abramowitz MK. Advances in management of chronic metabolic acidosis in chronic
280 kidney disease. *Current opinion in nephrology and hypertension*. 2019;28(5):409-16.
- 281 16. Sy J, Chen JLT, Kalantar-Zadeh K. New solutions to old problems-metabolic acidosis in chronic
282 kidney disease. *Annals of translational medicine*. 2020;8(19):1256.
- 283 17. Chen W, Abramowitz MK. Treatment of metabolic acidosis in patients with CKD. *American*
284 *journal of kidney diseases : the official journal of the National Kidney Foundation*. 2014;63(2):311-7.
- 285 18. Goraya N, Wesson DE. Management of the Metabolic Acidosis of Chronic Kidney Disease.
286 *Advances in chronic kidney disease*. 2017;24(5):298-304.
- 287 19. Goraya N, Simoni J, Jo C-H, Wesson DE. A Comparison of Treating Metabolic Acidosis in CKD
288 Stage 4 Hypertensive Kidney Disease with Fruits and Vegetables or Sodium Bicarbonate. *Clinical Journal*
289 *of the American Society of Nephrology*. 2013;8(3):371.
- 290 20. Goraya N, Simoni J, Jo C-H, Wesson DE. Treatment of metabolic acidosis in patients with stage 3
291 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and
292 preserves glomerular filtration rate. *Kidney International*. 2014;86(5):1031-8.

- 293 21. Goraya N, Munoz-Maldonado Y, Simoni J, Wesson DE. Fruit and Vegetable Treatment of Chronic
294 Kidney Disease-Related Metabolic Acidosis Reduces Cardiovascular Risk Better than Sodium
295 Bicarbonate. *American journal of nephrology*. 2019;49(6):438-48.
- 296 22. Goraya N, Munoz-Maldonado Y, Simoni J, Wesson DE. Treatment of Chronic Kidney Disease-
297 Related Metabolic Acidosis With Fruits and Vegetables Compared to NaHCO₃ Yields More
298 and Better Overall Health Outcomes and at Comparable Five-Year Cost. *Journal of Renal Nutrition*.
299 2021;31(3):239-47.
- 300 23. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of
301 Electronic Search Strategies: 2015 Guideline Statement. *Journal of Clinical Epidemiology*. 2016;75:40-6.
- 302 24. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. *Cochrane handbook for*
303 *systematic reviews of interventions*: John Wiley & Sons; 2019.
- 304 25. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting
305 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic*
306 *reviews*. 2015;4(1):1-9.
- 307 26. Scotland HI. Scottish Intercollegiate Guidelines Network (2021). Search filters [updated 22
308 August 2022. Available from: <https://www.sign.ac.uk/what-we-do/methodology/search-filters/>.
- 309 27. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for
310 assessing risk of bias in randomised trials. *bmj*. 2019;366.
- 311 28. Pathak M, Dwivedi SN, Deo S, Sreenivas V, Thakur B. Which is the preferred measure of
312 heterogeneity in meta-analysis and why? A revisit. *Biostat Biometrics Open Acc*. 2017;1:1-7.
- 313 29. Light RJ, Richard J, Light R, Pillemer DB. *Summing up: The science of reviewing research*: Harvard
314 University Press; 1984.
- 315 30. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical
316 test. *Bmj*. 1997;315(7109):629-34.
- 317 31. Kuczera P, Ciaston-Mogilska D, Oslizlo B, Hycik A, Wiecek A, Adamczak M. The Prevalence of
318 Metabolic Acidosis in Patients with Different Stages of Chronic Kidney Disease: Single-Centre Study.
319 *Kidney and Blood Pressure Research*. 2020;45(6):863-73.
- 320 32. Goraya N, Wesson DE. Clinical evidence that treatment of metabolic acidosis slows the
321 progression of chronic kidney disease. *Current opinion in nephrology and hypertension*. 2019;28(3):267-
322 77.
- 323 33. Remer T. Influence of nutrition on acid-base balance—metabolic aspects. *European journal of*
324 *nutrition*. 2001;40(5):214-20.
- 325 34. Siener R. Dietary Treatment of Metabolic Acidosis in Chronic Kidney Disease. *Nutrients*.
326 2018;10(4).
- 327 35. Rodrigues Neto Angélico L, Arces de Souza GC, Almeida Romão E, Garcia Chiarello P. Alkaline
328 Diet and Metabolic Acidosis: Practical Approaches to the Nutritional Management of Chronic Kidney
329 Disease. *Journal of Renal Nutrition*. 2018;28(3):215-20.

330

331